S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

$8.46
-1.72 (-16.90 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$8.36
Now: $8.46
$10.09
50-Day Range
$8.46
MA: $10.79
$13.09
52-Week Range
$5.36
Now: $8.46
$17.83
Volume224,685 shs
Average Volume204,392 shs
Market Capitalization$250.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.51 million
Book Value$7.16 per share

Profitability

Net Income$-56,020,000.00
Net Margins-7,291.37%

Miscellaneous

Employees71
Market Cap$250.21 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.


Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.86) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.07. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.08 million. Concert Pharmaceuticals had a negative net margin of 7,291.37% and a negative return on equity of 55.06%. View Concert Pharmaceuticals' Earnings History.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Concert Pharmaceuticals.

What price target have analysts set for CNCE?

7 Wall Street analysts have issued 12 month price targets for Concert Pharmaceuticals' shares. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $18.14 in the next year. This suggests a possible upside of 114.5% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

What is the consensus analysts' recommendation for Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

Has Concert Pharmaceuticals been receiving favorable news coverage?

News coverage about CNCE stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Concert Pharmaceuticals.

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 618,700 shares, an increase of 5.1% from the January 30th total of 588,400 shares. Based on an average trading volume of 209,800 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.9% of the shares of the company are sold short. View Concert Pharmaceuticals' Current Options Chain.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.27%), Bank of America Corp DE (6.05%), Ingalls & Snyder LLC (6.15%), Renaissance Technologies LLC (2.14%), State Street Corp (1.38%) and Prudential Financial Inc. (1.24%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss. View Institutional Ownership Trends for Concert Pharmaceuticals.

Which major investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., Perceptive Advisors LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Prudential Financial Inc., New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

Which major investors are buying Concert Pharmaceuticals stock?

CNCE stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., Alambic Investment Management L.P., Oxford Asset Management LLP, Geode Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $8.46.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $250.21 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  464 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  852
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel